PANalytical launches the Empyrean Nano edition
PTSM: Pharmaceutical Technology Sourcing and Management
The Empyrean Nano edition offers a combination of advanced X-ray scattering techniques.
PANalytical launched the Empyrean Nano edition in August 2016, a new hybrid laboratory instrument that offers a combination of advanced X-ray scattering techniques. From the experimental data, (nano)material researchers can deduce information about nanoscale structures, dimensions, in addition to order and disorder on the atomic level.
The Empyrean Nano edition supports all major elastic X-ray scattering techniques, namely ultra-small-angle X-ray scattering, small- and wide-angle X-ray scattering, SAXS on biological macromolecules, and total scattering. The instrument includes a high-resolution goniometer, a modular concept based on pre-aligned components, and detector technology. Empyrean Nano edition has the ability to characterize nanoparticles, colloids, protein solutions, surfactants, porous materials, polymers, nanocomposites, liquid crystals, and glasses.
Source: PANalytical
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
